.
BDTX financial statements
* Numbers in thousands
Year |
2019 | 2020 | TTM |
|---|---|---|---|
Capitalization * |
1 288 487 | 889 924 | 99 878 |
EV * |
1 133 821 | 864 060 | 864 060 |
Stock price $ |
39.48 | 24.77 | 2.78 |
Number of shares * |
32 636 | 35 927 | 35 927 |
EPS |
-1,08 | -1,87 | -1,87 |
Revenue * |
0 | 0 | 0 |
Net income * |
-35 258 | -67 254 | -67 254 |
Operating profit * |
-29 332 | -69 570 | -69 570 |
Total liabilities * |
205 452 | 21 912 | 21 912 |
Net debt * |
-154 666 | -25 864 | -25 864 |
Total assets * |
158 295 | 329 670 | 329 670 |
Equity * |
-47 157 | 307 758 | 307 758 |
Cash and investments * |
154 666 | 315 067 | 315 067 |
Over the past 10 years, the maximum capitalization of Black Diamond Therapeutics, Inc. is 1 288 487, the minimum is 889 924. Maximum net income 0, Minimum net income -67 254. The maximum price of BDTX shares is 39.48, the minimum price is 24.77.
.
BDTX valuation
Year |
2019 | 2020 | TTM |
|---|---|---|---|
P/E |
-36,54 | -13,23 | -1,49 |
P/B |
-27,32 | 2,89 | 0,32 |
P/S |
0,00 | 0,00 | 0,00 |
E/P |
-3% | -8% | -67% |
P/FCF |
-52,18 | -17,02 | -1,91 |
.
BDTX profitability
Year |
2019 | 2020 | TTM |
|---|---|---|---|
ROE |
75% | -22% | |
ROA |
-22% | -20% | |
ROIC |
-19% | -22% |